Brainstorm Cell Therapeutics Inc. (BCLI)

BCLI Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Income Operating Income Growth	-9.95	-9.95	-11.69	-21.44	-24.82	-24.54
Net Income Net Income Growth	-10.52	-10.31	-11.62	-17.19	-24.28	-24.46
Earnings Per Share EPS Growth	-0.95	-1.11	-2.31	-5.99	-9.97	-10.20
EPS Growth	-	-	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	0.02	0.03	0.19	1.3	2.98	22.09
Total Debt Total Debt Growth	1.37	1.18	1.02	1.28	4.09	5.08
Net Cash (Debt) Net Cash Growth	-1.35	-1.15	-0.83	0.03	-1.11	17.02
Net Cash Growth	-	-	-	-	-	-50.99%
Net Cash Per Share Net Cash Per Share Growth	-0.12	-0.12	-0.17	0.01	-0.46	7.05

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-	-6.98	-9.09	-20.46	-19.32	-26.27
Capital Expenditures CapEx Growth	-	-	-	-0.02	-0.03	-0.33
Free Cash Flow Free Cash Flow Growth	-	-6.98	-9.09	-20.48	-19.35	-26.6
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error